Galectin-3 is widely expressed in different cell types; thus interaction with LAG-3 serves to broaden LAG-3's immune regulatory impacts on tumor-infiltrating CD8+ T cells within the TME [75]. The gene discussed is LGALS3; the disease is neoplasm.